Chronic Rhinosinusitis With Nasal Polyps: Considering Systemic Management Approaches to Optimize Outcomes
Activity Description
This interactive program discusses foundational knowledge on chronic rhinosinusitis with nasal polyps (CRSwNP) with respect to patient quality of life, disease progress, and underlying immunologic processes. In addition, it reviews the efficacy and safety of standard and novel treatment options. This program also features whiteboard-style animation videos that illustrate the common underlying pathophysiological mechanisms involved in CRSwNP and explain the mechanism of action of new therapies for this condition.
Faculty Presenters
Antoine Azar, MD, FAAAAI
Clinical Director
Division of Allergy and Clinical Immunology
Assistant Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD
William Busse, MD
Emeritus Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
University of Wisconsin School of Medicine and Public Health
Madison, WI
Cecelia Damask, DO
Board-Certified Otolaryngologist
Lake Mary ENT and Allergy
Lake Mary, FL
Christine Franzese, MD
Professor of Clinical Otolaryngology
Director of Allergy
University of Missouri School of Medicine
Columbia, MO
Flavia Cecilia Lega Hoyte, MD
Associate Professor, Division of Allergy and Clinical Immunology
Director, Allergy and Clinical Immunology Fellowship
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver, CO
Thanai Pongdee, MD
Consultant, Division of Allergic Diseases
Joint Appointment, Division of Hematology
Assistant Professor of Medicine, College of Medicine and Science
Mayo Clinic
Rochester, MN
Jody Tversky, MD, FAAAAI
Former Clinical Director
Division of Allergy and Clinical Immunology
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Activity Planners
Sara Samuel, MSc, MPhil, MS
Clinical Content Manager
Med-IQ
Baltimore, MD
Laura Rafferty, ELS
Senior Editorial Manager
Med-IQ
Baltimore, MD
Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD
Amy Sison
Director of CME
Med-IQ
Baltimore, MD
Writers
Eileen McCaffrey, MA
Whippany, NJ
Haifa Kassis, MD
Boston, MA
Learning Objectives
Upon completion, participants should be able to:
Target Audience
This activity is intended for allergists/immunologists.
Statement of Need
Patients who have chronic rhinosinusitis with nasal polyps (CRSwNP) experience recurring nasal polyps that can greatly reduce their quality of life; however, many clinicians dismiss CRSwNP as simply a “chronic runny nose.” The current standard of care consists of symptomatic relief and surgery if less-invasive steroid treatments are insufficient. However, CRSwNP recurrence after surgery is common; in fact, rates are as high as 50% over the course of 3 years. Recent research has revealed an underlying immunologic cause for CRSwNP, which has informed the development of new and emerging biologic therapies that target type 2 inflammation. Thus, healthcare providers can benefit from education on current evidence regarding CRSwNP and management approaches, as well as best practices for facilitating care coordination.
Accreditation/Designation Statements
Provided by Med-IQ. Powered by Gather-ed.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this other activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Off-label/unapproved drug uses or products are mentioned within this activity.
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Antoine Azar, MD, FAAAAI
Consulting fees/advisory boards: argenX, CSL, Optinose, X4 Pharmaceuticals
Contracted research: Grifols, X4 Pharmaceuticals
William Busse, MD
Consulting fees/advisory boards: AstraZeneca, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Fees received for promotional/non-CE activities: Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Cecelia Damask, DO
Consulting fees/advisory boards: AstraZeneca, Audigy Medical, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Fees received for promotional/non-CE activities: ALK, AstraZeneca, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Optinose, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Contracted research: AstraZeneca, GlaxoSmithKline, Optinose
Christine Franzese, MD
Consulting fees/advisory boards: Genentech, GlaxoSmithKline, Optinose, Regeneron Pharmaceuticals, Inc.
Fees received for promotional/non-CE activities: AstraZeneca, Genentech, GlaxoSmithKline, Optinose, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Contracted research: AstraZeneca, Bellus Health, GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Optinose, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc., Shionogi
Flavia Cecilia Lega Hoyte, MD
Consulting fees/advisory boards: AstraZeneca
Contracted research: Genentech, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries Ltd.
Other: (Unbranded Speaker): AstraZeneca, GlaxoSmithKline
Jody Tversky, MD, FAAAAI
Receipt of intellectual property right/patent holder: Flare Diagnostics, LLC
Consulting fees/advisory boards: BrioPryme Therapeutics
Fees received for promotional/non-CME/CE activities: AstraZeneca
Contracted research: AstraZeneca, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
The writers, peer reviewers, and activity planners have no financial relationships to disclose.
Contact Information
For CME questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Complimentary CME
This activity is available free of charge to participants.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Copyrighted
